LETTER TO EDITOR

Antimicrobial Resistance – A Silent Pandemic

Sneka P¹, Sangamithra V²*, Mahalakshmi K³

¹,²Bhaarath Medical College and Hospital, BIHER, Chennai, India
³Sree Balaji Dental College and Hospital, BIHER, Chennai, India

DOI: 10.55489/njcm.140120232625

Key words: Research related to antimicrobial use, regional variation, interventional strategies

Dear Editor,

Antimicrobial resistance (AMR) has emerged as a serious and major challenge to human health due to worrying levels it has reached throughout the world. This issue if not handled will move us to the pre antibiotic period with no drug left in choice to treat serious life consuming infections.

Current statistics reveal around 1.3 million deaths annually are due to antimicrobial resistance which is more than due to HIV/AIDS or Malaria. It is predicted AMR might consume 10 million lives by 2050. We are already close to the predicted number. Besides this it also poses a serious socio-economic burden globally. The World Bank has cautioned that, by 2050, burden posed by drug resistance would be higher than that caused by 2008 financial crisis and 24 million people will succumb by 2030 due to the impact of AMR on economy and health. To control and contain AMR we need a joint action from variety of sectors. In many countries, antimicrobials have become over the counter (OTC) drugs, India being no exception. India rates of drug resistance are the leading in the world. In spite of being the largest producer and exporter of drugs, AMR is high due to lack of effective drug surveillance system. Policies have been formulated at National level but what is needed is policies at local community level for effective and justifiable use of antimicrobials to withhold and curb the emerging resistance. Children under 5 are most vulnerable to AMR.

Data from CDC reveals 30% of antibiotics being prescribed are unjustifiable or unnecessary. From being a submerged and unaddressed problem, a clearer picture of the AMR burden has emerged. Superbugs are the outcome of our prolonged failure to preserve antibiotics. Study from WHO and Lancet reveals drivers of AMR to be multifaceted indicating the need for one health initiative saying human health is directly related to animals and environment. WHO has released the priority pathogens list in 2017 as a result of evolving resistance. Table 1 shows the WHO list of priority pathogens.

ARTICLE INFO

Financial Support: None declared
Conflict of Interest: None declared
Received: 06-12-2022, Accepted: 06-01-2023, Published: 31-01-2023
*Correspondence: Dr. V. SANGAMITHRA (Email: sangamithrav1978@gmail.com)

How to cite this article:

Copy Right: The Authors retain the copyrights of this article, with first publication rights granted to Medsci Publications.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-Share Alike (CC BY-SA) 4.0 License, which allows others to remix, adapt, and build upon the work commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

www.njcmindia.com | pISSN09763325 | eISSN22296816 | Published by Medsci Publications

@2023 National Journal of Community Medicine | Volume 14 | Issue 01 | January 2023
Table 1: WHO list of priority pathogens.7

<table>
<thead>
<tr>
<th>Priority list</th>
<th>Organism</th>
<th>Resistant Antibiotic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Critical Priority</td>
<td>Acinetobacter</td>
<td>Carbapenem</td>
</tr>
<tr>
<td></td>
<td>Pseudomonas</td>
<td>Carbapenem</td>
</tr>
<tr>
<td></td>
<td>Enterobacterales</td>
<td>Carbapenem, 3rd generation cephalosporin</td>
</tr>
<tr>
<td>High Priority</td>
<td>Enterococcus</td>
<td>Vancomycin</td>
</tr>
<tr>
<td></td>
<td>Staphylococcus</td>
<td>Methicillin</td>
</tr>
<tr>
<td></td>
<td>Helicobacter</td>
<td>Clarithromycin</td>
</tr>
<tr>
<td></td>
<td>Campylobacter</td>
<td>Fluoroquinolone</td>
</tr>
<tr>
<td></td>
<td>Salmonella</td>
<td>Fluoroquinolone</td>
</tr>
<tr>
<td></td>
<td>Neisseria gonorrhoea</td>
<td>3rd generation cephalosporin, Fluoroquinolone</td>
</tr>
<tr>
<td>Medium Priority</td>
<td>Streptococcus pneumonia</td>
<td>Penicillin</td>
</tr>
<tr>
<td></td>
<td>Haemophilus influenza</td>
<td>Ampicillin</td>
</tr>
<tr>
<td></td>
<td>Shigella species</td>
<td>Fluoroquinolone</td>
</tr>
</tbody>
</table>

Carbapenem resistance in India is 20 times more common than in U.S. ICMR revealed 85% resistance of Acinetobacter spp to carbapenem, genus contributing to 20% of admissions in ICU setting.7 Data from GLASS study revealed MRSA rates to be 25%, E.coli resistance to 3rd generation cephalosporins as 36.6% and alarming level of carbapenem resistance in Acinetobacter ie., 65%.8 Common infections could once again become deadly killers if we are unable to treat them with antimicrobials.

Development and spread of resistance par exceed our innovations and developments. In the past 3 decades we have developed only 2 new classes of drugs for Gram positives with no developments for drug resistant Gram-negative bacteria.9 We need to strengthen our funds on vaccines and drugs to combat the death due to AMR. Adequate surveillance at community level through epidemiological and microbiological tools are needed to analyse the situation and to fill the gap in knowledge on microbes.

What can be done at hospital level is adoption of Infection control measures and antimicrobial stewardship through regular training of health care professionals and prescriptions audits. We need to watch antimicrobial use in food animals by strengthening veterinary medicine.

To conclude, antimicrobial resistance is a multifaceted problem which if not taken actions can have a devastating health, social and economic impact.

REFERENCES


6. European Centre for Disease Prevention and Control. WHO publishes list of bacteria for which new antibiotics are urgently needed. Available at: https://www.who.int/news/item/27-02-2017


